News

SAGA expands research collaboration with University College London Cancer Institute

  LUND, Sweden — /June 17, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announced an expanded research collaboration with Professor Charles Swanton, at the University College London (UCL) Cancer Institute.   Last…

SAGA Diagnostics achieves ISO 17025 accreditation by SWEDAC for mutation testing services

  LUND, Sweden — /June 15, 2021/ — SAGA Diagnostics AB (“SAGA”), today announced that it has successfully been accredited to the ISO 17025 standard for its leading-edge mutation detection laboratory services designed to radically improve cancer diagnosis, monitoring, and treatment outcomes.  Granted by SWEDAC, the Swedish Board for Accreditation…

Now recruiting: Molecular Diagnostics Scientist Digital PCR

Molecular Diagnostics Scientist, Digital PCR   Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival?   SAGA Diagnostics AB is seeking a talented and highly motivated digital PCR (dPCR) scientist with strong interest in advancing our mission to revolutionize…

SAGAsafe® technology utilized in new study of ESR1 mutations in breast cancer

  LUND, Sweden — /April 22, 2021/ — ESR1 mutations are found in primary breast cancers prior to therapy initiation and are associated to worse relapse-free and overall survival. These results were reported today by a group of researchers from Lund University and Skåne University Hospital in a new studied…

Now recruiting: Molecular Diagnostics Scientist NGS

Molecular Diagnostics Scientist, NGS   Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival?   SAGA Diagnostics AB is seeking a talented and highly motivated NGS scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through…

SAGA Diagnostics co-financed in the EU Commission’s TIGER grant of EUR 6.9 million led by eTheRNA Immunotherapies

  LUND, Sweden — /March 23, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the participation in the EU H2020 funded consortium grant TIGER together with seven other partners and led by…

SAGA presenting at the EACR-OECI virtual conference: Molecular Pathology Approach to Cancer on March 23-24

Molecular pathology is revolutionizing clinical practice in oncology and pathology paving the way for precision medicine, and has evolved into a growing research field.     SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, is proud…

SAGA awarded €200,000 grant from Sweden’s innovation agency Vinnova

  LUND, Sweden — /March 16, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has been awarded a grant of 2.0 MSEK (~ €200,000) from the Swedish Governmental Agency for Innovation Systems (Vinnova) under the…

SAGA Diagnostics enters into Agreement with Alligator Bioscience in the phase 1b/2 OPTIMIZE-1 trial

LUND, Sweden — /February 25, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into a service agreement with Alligator Bioscience, a Swedish clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs.   SAGA…

SAGA enters collaboration with Institut Curie in the MONDRIAN trial

LUND, Sweden — /February 2, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, announced today its collaboration with the French comprehensive cancer center Institut Curie in the MONDRIAN breast cancer clinical trial.   The…